東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to targeted therapies in ...

Ling, Silvia CW.

FindBook

Google Book

Amazon

博客來

Resistance to targeted therapies in multiple myeloma

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to targeted therapies in multiple myeloma/ edited by Silvia CW Ling, Steven Trieu.
其他作者:	Ling, Silvia CW.
出版者:	Cham :Springer International Publishing : : 2021.,
面頁冊數:	xvii, 154 p. :ill., digital ;24 cm.
內容註:	1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
Contained By:	Springer Nature eBook
標題:	Drug resistance in cancer cells. -
電子資源:	https://doi.org/10.1007/978-3-030-73440-4
ISBN:	9783030734404

Resistance to targeted therapies in multiple myeloma
Resistance to targeted therapies in multiple myeloma[electronic resource] /edited by Silvia CW Ling, Steven Trieu. - Cham :Springer International Publishing :2021. - xvii, 154 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.222196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.22..

1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

ISBN: 9783030734404

Standard No.: 10.1007/978-3-030-73440-4doiSubjects--Topical Terms:

658434
Drug resistance in cancer cells.

LC Class. No.: RC280.B6

Dewey Class. No.: 616.99418

Resistance to targeted therapies in multiple myeloma
LDR:02863nmm a2200337 a 4500 001 2241971
003 DE-He213
005 20210723092404.0
006 m d
007 cr nn 008maaau
008 211207s2021 sz s 0 eng d
020 $a 9783030734404 $q (electronic bk.)
020 $a 9783030734398 $q (paper)
024 7 $a 10.1007/978-3-030-73440-4 $2 doi
035 $a 978-3-030-73440-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B6
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99418 $2 23
090 $a RC280.B6 $b R433 2021
245 0 0 $a Resistance to targeted therapies in multiple myeloma $h [electronic resource] / $c edited by Silvia CW Ling, Steven Trieu.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xvii, 154 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.22
505 0 $a 1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
520 $a Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
650 0 $a Drug resistance in cancer cells. $3 658434
650 0 $a Multiple myeloma $x Treatment. $3 1074136
650 1 4 $a Cancer Research. $3 891172
650 2 4 $a Immunology. $3 611031
700 1 $a Ling, Silvia CW. $3 3500675
700 1 $a Trieu, Steven. $3 3500676
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.22. $3 3500677
856 4 0 $u https://doi.org/10.1007/978-3-030-73440-4
950 $a Biomedical and Life Sciences (SpringerNature-11642)